Fmr LLC grew its position in NeuroDerm Ltd. (NASDAQ:NDRM) by 30.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 260,039 shares of the biotechnology company’s stock after acquiring an additional 60,039 shares during the period. Fmr LLC owned 0.99% of NeuroDerm worth $7,775,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Van ECK Associates Corp raised its position in NeuroDerm by 11.0% during the 2nd quarter. Van ECK Associates Corp now owns 4,723 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 468 shares during the last quarter. Vanguard Group Inc. bought a new position in NeuroDerm during the 2nd quarter worth $210,000. Oppenheimer & Co. Inc. bought a new position in NeuroDerm during the 1st quarter worth $223,000. Nationwide Fund Advisors bought a new position in NeuroDerm during the 1st quarter worth $226,000. Finally, HighTower Advisors LLC bought a new position in NeuroDerm during the 1st quarter worth $242,000. Institutional investors own 52.39% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Fmr LLC Increases Stake in NeuroDerm Ltd. (NDRM)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/11/02/fmr-llc-increases-stake-in-neuroderm-ltd-ndrm.html.
Several research analysts recently issued reports on NDRM shares. Zacks Investment Research lowered NeuroDerm from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Jefferies Group LLC reaffirmed a “buy” rating and set a $42.00 target price on shares of NeuroDerm in a research report on Monday, August 14th. Raymond James Financial, Inc. lowered NeuroDerm from an “outperform” rating to a “market perform” rating and set a $39.00 target price for the company. in a research report on Monday, July 24th. BidaskClub raised NeuroDerm from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, Deutsche Bank AG started coverage on NeuroDerm in a research report on Friday, July 21st. They set a “buy” rating and a $47.00 target price for the company. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $45.86.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.